Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 to 75 years old
- People diagnosed with breast cancer that has not spread to other parts of the body, where hormone therapy (such as anti-oestrogen or anti-aromatase medication) has been recommended by a medical team
- People with a general health and activity level rated at 2 or below on a standard medical scale (meaning able to carry out some daily activities, even if limited) (confirm with trial site)
- People who can read and understand French
- People who have access to an internet connection, as some parts of the trial use an online platform
- People who have been fully informed about the study and have signed a consent form agreeing to take part
- People who are covered by the French social security system or an equivalent scheme
Who may not be able to join:
- People whose cancer has spread to other parts of the body (stage IV/metastatic cancer)
- People currently receiving hormone therapy before surgery (neoadjuvant hormone therapy)
- People who have already started hormone therapy before being enrolled in the study
- People who have previously had another cancer treated with radiotherapy, chemotherapy, or hormone therapy, where treatment finished less than 2 years ago
- For the active treatment group: people who are unable to travel to the hospital for an initial assessment day and group workshops, or for whom following the programme would be difficult due to location, physical ability, or other reasons as judged by the trial team
- For the comparison group: people for whom telephone nursing support lasting 2 months or more, or more than 4 sessions of therapeutic education, is already planned
- People who are pregnant or breastfeeding
- People with a documented history of cognitive or psychiatric disorders
- People who decline to participate, or people who are legally under guardianship or a similar form of legal protection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Séverine Breysse, Centre Hospitalier Emile Roux
Phone: +33 4 71 04 35 38
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To compare the effectiveness of adding a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone on the management of adverse events related to adjuvant hormone therapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.